Cancer cells can shed a protein called DDR1 that helps collagen proteins create dense barriers around tumors. A study in mice showed these barriers can prevent immune cells from entering and killing tumors.
An update has been added to the October 13, 2021, Cancer Currents story on a clinical trial called KEYNOTE-716, which tested pembrolizumab (Keytruda) in people with early-stage melanoma who had undergone surgery to remove their tumors. On December 3, the Food and Drug Administration approved pembrolizumab for this use based on the trial results.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892
No comments:
Post a Comment